Chronic Hepatitis B
490
42
74
206
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
61 trials with published results (12%)
Research Maturity
206 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
6.7%
33 terminated out of 490 trials
86.2%
-0.3% vs benchmark
31%
154 trials in Phase 3/4
30%
61 of 206 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 206 completed trials
Clinical Trials (490)
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
Efficacy of VTP-300 in Chronic Hepatitis B Infection
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
Assessment of Treatment Adherence and Associated Factors in Chronic HepB Patients Supported by HBVCare
A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
Adaptability of an Undetectable = Untransmissible Model for HBV